Reverse cholesterol transport

Reverse cholesterol transport (RCT) is a multi-step process that facilitates the transport of cholesterol from peripheral tissues back to the liver for excretion, thus preventing the accumulation of cholesterol in the arterial wall. This process is considered a crucial protective mechanism against the development of atherosclerosis, a disease characterized by the buildup of cholesterol and other substances in and on the artery walls.

Process of Reverse Cholesterol Transport

RCT begins with the efflux of cholesterol from peripheral cells to apoA-I, a process facilitated by the ABCA1 transporter. The interaction between apoA-I and ABCA1 results in the formation of nascent HDL particles, which are discoidal in shape and rich in unesterified cholesterol.

The unesterified cholesterol in nascent HDL particles is then esterified by the enzyme LCAT, which is activated by apoA-I. The esterification of cholesterol results in the formation of mature spherical HDL particles, which contain a core of cholesteryl esters.

Mature HDL particles can deliver cholesterol to the liver directly via the SR-BI receptor or indirectly via the transfer of cholesteryl esters to apoB-containing lipoproteins, such as LDL and VLDL, in a process mediated by the CETP.

The cholesterol delivered to the liver is then excreted into the bile either directly or after conversion to bile acids through the process of bile acid synthesis.

Clinical Significance

RCT plays a crucial role in maintaining cholesterol homeostasis and protecting against atherosclerosis. Impaired RCT has been associated with an increased risk of coronary artery disease and other forms of cardiovascular disease. Therefore, strategies aimed at enhancing RCT, such as increasing HDL levels or improving HDL function, have been proposed as potential therapeutic approaches for the prevention and treatment of cardiovascular disease.

‎

‎

‎